Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452500 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)
A Phase 2 study of PTSD, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT04452500 is a Phase 2 study of PTSD that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 40 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04452500, a Phase 2 study of PTSD, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CORT108297
Study Locations (2)
Alabama
- Tuscaloosa VA Medical Center, Tuscaloosa, AL - Tuscaloosa
California
- San Francisco VA Medical Center, San Francisco, CA - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-10-15 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04452500
The ClinicalTrials.gov registry entry for NCT04452500 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04452500 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04452500 about?
NCT04452500 is a clinical study titled "Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)". The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.
What is the current status of trial NCT04452500?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-10-15. Estimated completion is 2026-12-31.
What conditions does trial NCT04452500 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT04452500?
The interventions under investigation include: Placebo (DRUG), CORT108297 (DRUG).
Who is sponsoring clinical trial NCT04452500?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04452500 being conducted?
This trial has 2 study locations across Alabama, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.